PRAME and lymphoma: The association of EZH2 with the PRAME promoter and the transcriptional repression of PRAME in EZH2-mut lymphomas prompted us to explore whether EZH2-targeted therapy might induce PRAME and reactivate antitumor immunity in vivo.